• Placebo-Controlled Trial of Mianserin HCl

  2026-10-08

  A 1978 double-blind, placebo-controlled inpatient trial tested whether mianserin had antidepressant activity beyond the effects observed in comparisons with established tricyclic drugs. The study reported improvement in depressive symptoms and sleep, while the immediate sleep response also highlighted the difficulty of separating antidepressant benefit from sedative effects during a short trial.

• From Nuclear Guides to Cytosolic RNA Control

  2026-10-07

  A source-grounded perspective on how U1-driven CRISPR RNAs address a central Cas13 bottleneck: guide localization. The article connects the reported mechanism to translational evidence standards, reagent governance, and the distinct role of DNase I (GMP-grade) in broader development strategies.

• Puromycin Aminonucleoside: Evidence and Limits

  2026-10-07

  Puromycin aminonucleoside is the aminonucleoside moiety of puromycin and a widely used nephrotoxic agent for studying podocyte injury, proteinuria, and glomerular pathology. Evidence supports its value as a mechanistic disease model, but PAN-induced lesions should not be treated as a complete reproduction of human focal segmental glomerulosclerosis.

• Puromycin aminonucleoside: Reading Injury Models

  2026-10-06

  Puromycin aminonucleoside is more than a nephrotoxic reagent: it is a framework for studying how podocyte damage becomes measurable glomerular dysfunction. This evidence-centered guide connects cellular morphology, proteinuria, FSGS-like lesions, transporter context, and lessons from a glioma biomarker study without turning interpretation into a protocol.

• DNMT3B, Nanaomycin A, and NEPC Plasticity

  2026-10-06

  A translational perspective on how DNMT3B may connect androgen-directed therapy, stemness, and neuroendocrine lineage plasticity in prostate cancer—and where (S,S)-Nanaomycin A fits as a research tool.

• Epoxomicin in Proteasome and ER Stress Research

  2026-10-05

  This overview places Epoxomicin within proteasome and protein-quality-control research, using the supplied 2024 study on UBR1 and UBR2 to distinguish established findings from conceptual applications and vendor-reported properties. It emphasizes evidence strength, interpretation limits, and the absence of direct Epoxomicin-specific validation in that study.

• 2-Deoxy-D-glucose: Metabolic Research Context

  2026-10-05

  A source-grounded overview of 2-Deoxy-D-glucose and 2-DG as metabolic perturbation tools, comparing supplier-reported cancer and antiviral findings with the 2026 Cell Research study of lactate–GPR81 signaling while emphasizing evidence strength, provenance, and translational limits.

• Afatinib in Gastric Cancer Model Interpretation

  2026-10-04

  Afatinib, also known as BIBW 2992, provides a powerful lens for studying ErbB-dependent signaling in complex gastric cancer models. This article explains how patient-derived assembloids can distinguish tumor-intrinsic drug response from stromal modulation while clarifying the evidence boundaries of current research.

• Sulfo-NHS-Biotin and the Next Era of Cell Profiling

  2026-10-03

  Sulfo-NHS-Biotin connects covalent amine labeling with emerging single-cell functional profiling. This thought-leadership analysis examines its mechanistic value, translational boundaries, and strategic relevance without treating product chemistry as a substitute for functional validation.

• Sulfo-NHS-Biotin Workflows for Nanovial Assays

  2026-10-02

  Sulfo-NHS-Biotin combines selective amine labeling with aqueous, cell-compatible handling for surface phenotyping, capture assays, and protein interaction studies. Paired with capped nanovials, it offers a practical route to connect molecular labeling with high-throughput single-cell growth, secretion, and co-culture measurements.

• PTEN mRNA Nanoparticles Reverse Trastuzumab Resistance

  2026-10-01

  The reference study developed tumor-microenvironment-responsive nanoparticles for systemic PTEN mRNA delivery and used PTEN restoration to counter persistent PI3K/Akt signaling in trastuzumab-resistant HER2-positive breast cancer models. Its main contribution is a delivery strategy that links tumor-selective nanoparticle activation with transient tumor-suppressor replacement, providing a mechanistic basis for resensitizing resistant tumors to trastuzumab.

• Machine Learning for Cross-Cell-Line MoA Prediction

  2026-10-01

  Warchal, Dawson, and Carragher evaluated an ensemble tree classifier and a convolutional neural network for predicting compound mechanism of action from high-content cell images. The study shows that deep learning can match feature-based classification within a cell line, but feature-based models may transfer more reliably to an unseen cell line.

• Podophyllotoxin Beyond Mitotic Arrest in Translation

  2026-09-30

  Podophyllotoxin is more than a conventional microtubule perturbagen: it is a mechanistic entry point for connecting mitotic arrest, apoptosis, multidrug resistance, and translational assay design. This thought-leadership guide explains how to position the parent compound, interpret derivative data, control autophagy claims, and build reproducible cancer research workflows.

• AMD-070 Hydrochloride: Assay Design Guide

  2026-09-30

  AMD-070 hydrochloride is a CXCR4 antagonist with applications spanning receptor pharmacology, HIV entry inhibition, and migration biology. This assay-focused guide explains how to distinguish CXCR4-specific effects from membrane, osmotic, and formulation artifacts using lessons from a classic protoplast study.

• Sulfo-NHS-Biotin for CADASIL Assay Design

  2026-09-29

  Learn how Sulfo-NHS-Biotin can translate CADASIL vascular pathology into compartment-specific protein assays. This guide connects amine-reactive surface labeling with the NOTCH3 R545C model while distinguishing established evidence from proposed workflows.

8103 records 1/541 page Next 12345 下5页 Last page